NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $215.23 -1.17 (-0.54%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOptions ChainOwnershipRatingsSEC FilingsShort Interest About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$214.03▼$216.0750-Day Range$173.44▼$216.9652-Week Range$137.63▼$217.12Volume1.39 million shsAverage Volume1.66 million shsMarket Capitalization$10.83 billionAssets Under Management$10.86 billionDividend Yield0.19%Net Expense Ratio0.44%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.44%0.55%0.57%0.54%0.53%Other Expenses0.00%0.52%0.53%0.39%0.54%Total Expense0.44%0.76%0.75%0.69%0.73%Fee Waiver0.00%-0.85%-0.67%-0.41%-0.68%Net Expense0.44%0.58%0.63%0.61%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News HeadlinesAmid the chip bear market, healthcare is breaking out: Chart of the dayAugust 21, 2026 | msn.comModerna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third SessionAugust 21, 2026 | 247wallst.comThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's pullback from highs above 4000 an ounce. Yet top junior mining assets remain priced as if gold were still stuck near 1800 an ounce, a gap analyst Garrett Goggin calls the Golden Anomaly. With record cash on hand, majors may soon be forced to buy juniors to secure future production.August 26 at 1:00 AM | Golden Portfolio (Ad)Biotech Is Booming, But These 2 Stocks Missed the MemoAugust 20, 2026 | benzinga.comSector Update: Healthcare Stocks Flat to Lower Pre-Bell FridayAugust 14, 2026 | finance.yahoo.comThese New Drugs Could Fuel Fresh Highs for Biotech and Pharma StocksAugust 7, 2026 | barrons.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $168.77 on January 1st, 2026. Since then, IBB stock has increased by 27.9% and is now trading at $215.87. When did iShares Biotechnology ETF's stock split? iShares Biotechnology ETF's stock split before market open on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly issued shares were issued to shareholders after the closing bell on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? iShares Biotechnology ETF's top institutional investors include Janney Montgomery Scott LLC (1.32%), Apella Capital LLC (0.12%), HighTower Advisors LLC (0.09%) and HighTower Advisors LLC (0.09%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings252 Fund Statistics Assets Under Management$10.86 billion Average Daily Volume$1.56 million Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume1,466 Put Options306 Call Options1,160 Short Interest10,440,435 shs Miscellaneous Outstanding Shares50,300,000Beta0.70 Creation Unit50,000 Creation Fee$614.00 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report Top 10 IBB HoldingsAmgen (NASDAQ:AMGN)Holding Weight: 8.63%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.91%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.20%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 6.08%argenex (NASDAQ:ARGX)Holding Weight: 3.32%Natera (NASDAQ:NTRA)Holding Weight: 3.17%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 2.91%Biogen (NASDAQ:BIIB)Holding Weight: 2.30%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.28%Illumina (NASDAQ:ILMN)Holding Weight: 2.16%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump Unleashes "Banned" American FuelA newly reopened American mine holds a fuel source so potent that one pound can generate as much energy as 16,...Monument Traders Alliance | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBuy this stock todayMost tech companies skip dividends entirely. This one doesn't, paying shareholders like clockwork while flying...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
